Brian Lian Ph.D.
Net Worth

Last updated:

What is Brian Lian Ph.D. net worth?

The estimated net worth of Dr. Brian Lian Ph.D. is at least $69,422,997 as of 31 Jan 2024. He owns shares worth $55,263,121 as insider, has earned $12,403,876 from insider trading and has received compensation worth at least $1,756,000 in Viking Therapeutics, Inc..

What is the salary of Brian Lian Ph.D.?

Dr. Brian Lian Ph.D. salary is $878,000 per year as Pres, Chief Executive Officer & Director in Viking Therapeutics, Inc..

How old is Brian Lian Ph.D.?

Dr. Brian Lian Ph.D. is 59 years old, born in 1966.

What stocks does Brian Lian Ph.D. currently own?

As insider, Dr. Brian Lian Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Viking Therapeutics, Inc. (VKTX) Pres, Chief Executive Officer & Director 2,264,882 $24.4 $55,263,121

What does Viking Therapeutics, Inc. do?

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

VKTX logo
VKTX
Viking Therapeutics, Inc.
$24.4

Brian Lian Ph.D. insider trading

Viking Therapeutics, Inc.

Dr. Brian Lian Ph.D. has made 10 insider trades between 2023-2024, according to the Form 4 filled with the SEC. Most recently he sold 45,000 units of VKTX stock worth $1,122,750 on 31 Jan 2024.

The largest trade he's ever made was exercising 155,000 units of VKTX stock on 17 Apr 2023. As of 31 Jan 2024 he still owns at least 2,264,882 units of VKTX stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock, par value $0.00001 per share 45,000 $24.95 $1,122,750
Sale
Common Stock, par value $0.00001 per share 40,000 $24.45 $978,000
Option
Common Stock, par value $0.00001 per share 85,000 $1.23 $104,550
Option
Stock Option (right to buy) 85,000 $1.23 $104,550
Sale
Common Stock, par value $0.00001 per share 35,000 $23.95 $838,250
Option
Stock Option (right to buy) 35,000 $1.23 $43,050
Option
Common Stock, par value $0.00001 per share 35,000 $1.23 $43,050
Sale
Common Stock, par value $0.00001 per share 45,000 $22.45 $1,010,250
Sale
Common Stock, par value $0.00001 per share 35,000 $21.45 $750,750
Option
Stock Option (Right to Buy) 125,000 $2.15 $268,750
Option
Common Stock, par value $0.00001 per share 125,000 $2.15 $268,750
Sale
Common Stock, par value $0.00001 per share 155,000 $20.45 $3,169,750
Option
Stock Option (right to buy) 54,336 $1.88 $102,152
Option
Common Stock, par value $0.00001 per share 54,336 $1.88 $102,152
Sale
Common Stock, par value $0.00001 per share 79,336 $18.45 $1,463,749
Sale
Common Stock, par value $0.00001 per share 22,000 $17.85 $392,700
Option
Common Stock, par value $0.00001 per share 67,970 $9.49 $645,035
Sale
Common Stock, par value $0.00001 per share 67,970 $17.45 $1,186,077
Option
Stock Option (Right to Buy) 67,970 $9.49 $645,035
Sale
Common Stock, par value $0.00001 per share 88,000 $16.95 $1,491,600
Option
Stock Option (Right to Buy) 19,530 $9.49 $185,340
Option
Stock Option (Right to Buy) 115,852 $1.23 $142,498
Option
Common Stock, par value $0.00001 per share 115,852 $1.23 $142,498
Option
Common Stock, par value $0.00001 per share 19,530 $9.49 $185,340

Viking Therapeutics key executives

Viking Therapeutics, Inc. executives and other stock owners filed with the SEC: